TY - JOUR
T1 - Event rates and incidence of post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves
T2 - exposure-stratified prospective cohort study in Moscow (StopCOVID)
AU - Sechenov StopCOVID Research Team
AU - Pazukhina, Ekaterina
AU - Rumyantsev, Mikhail
AU - Baimukhambetova, Dina
AU - Bondarenko, Elena
AU - Markina, Nadezhda
AU - El-Taravi, Yasmin
AU - Petrova, Polina
AU - Ezhova, Anastasia
AU - Andreeva, Margarita
AU - Iakovleva, Ekaterina
AU - Bobkova, Polina
AU - Pikuza, Maria
AU - Trefilova, Anastasia
AU - Abdeeva, Elina
AU - Galiautdinova, Aysylu
AU - Filippova, Yulia
AU - Bairashevskaia, Anastasiia
AU - Zolotarev, Aleksandr
AU - Bulanov, Nikolay
AU - DunnGalvin, Audrey
AU - Chernyavskaya, Anastasia
AU - Kondrikova, Elena
AU - Kolotilina, Anastasia
AU - Gadetskaya, Svetlana
AU - Ivanova, Yulia V
AU - Turina, Irina
AU - Eremeeva, Alina
AU - Fedorova, Ludmila A
AU - Comberiati, Pasquale
AU - Peroni, Diego G
AU - Nekliudov, Nikita
AU - Genuneit, Jon
AU - Reyes, Luis Felipe
AU - Brackel, Caroline L H
AU - Mazankova, Lyudmila
AU - Miroshina, Alexandra
AU - Samitova, Elmira
AU - Borzakova, Svetlana
AU - Carson, Gail
AU - Sigfrid, Louise
AU - Scott, Janet T
AU - McFarland, Sammie
AU - Greenhawt, Matthew
AU - Buonsenso, Danilo
AU - Semple, Malcolm G
AU - Warner, John O
AU - Olliaro, Piero
AU - Osmanov, Ismail M
AU - Korsunskiy, Anatoliy A
AU - Munblit, Daniel
N1 - Funding Information:
DM co-leads the PC-COS project, developing Core Outcome Set for post-COVID-19 condition, outside the submitted work. LFR reports grants and personal fees from Merck and Pfizer and personal fees from GSK, outside the submitted work. LS received support by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135], outside the submitted work. All other authors have no conflicts of interest relevant to this article to disclose.
Funding Information:
We are very grateful to the Z.A. Bashlyaeva Children’s Municipal Clinical Hospital and G.N. Speransky Children’s City Clinical Hospital No. 9 clinical staff and to the patients, parents, carers, and families for their kindness and understanding during these difficult times of COVID-19 pandemic. We would like to express our very great appreciation to ISARIC Global COVID-19 follow-up working group for the survey development. We are very thankful to FLIP, Eat & Talk, Luch, Black Market, and Academia for providing us the workspace in time of need and their support of COVID-19 research. Finally, we would like to extend our gratitude to the Global ISARIC team, the ISARIC global adult and paediatric COVID-19 follow-up working group, and ISARIC Global support centre for their continuous support and expertise and for the development of the outbreak ready standardised protocols for the data collection. Sechenov Stop COVID Research Team (group authors) Khazhar Aktulaeva1, Islamudin Aldanov1, Nikol Alekseeva1, Ramina Assanova1, Asmik Avagyan1, Irina Babkova1, Lusine Baziyants1, Anna Berbenyuk1, Tatiana Bezbabicheva1, Julia Chayka1, Iuliia Cherdantseva1, Yana Chervyakova1, Tamara Chitanava1, Alexander Chubukov1, Natalia Degtiareva1, Gleb Demyanov1, Semen Demyanov1, Salima Deunezhewa1, Aleksandr Dubinin1, Anastasia Dymchishina1, Murad Dzhavadov1, Leila Edilgireeva1, Yulia Filippova1, Veronika Filippova1, Yuliia Frumkina1, Anastasia Gorina1, Cyrill Gorlenko1, Marat Gripp1, Mariia Grosheva1, Eliza Gudratova1, Elena Iakimenko1, Margarita Kalinina1, Ekaterina Kharchenko1, Anna Kholstinina1, Bogdan Kirillov1, Herman Kiseljow1, Natalya Kogut1, Polina Kondrashova1, Irina Konova2, Mariia Korgunova1, Anastasia Kotelnikova1, Alexandra Krupina1, Anna Kuznetsova1, Anastasia Kuznetsova1, Anna S. Kuznetsova1, Anastasia Laevskaya1, Veronika Laukhina1, Baina Lavginova1, Yulia Levina1, Elza Lidjieva1, Anastasia Butorina1, Juliya Lyaginskaya1, Ekaterina Lyubimova1, Shamil Magomedov1, Daria Mamchich1, Rezeda Minazetdinova1, Artemii Mingazov1, Aigun Mursalova1, Daria Nikolaeva1, Alexandra Nikolenko1, Viacheslav Novikov1, Georgiy Novoselov1, Ulyana Ovchinnikova1, Veronika Palchikova1, Kira Papko1, Mariia Pavlova1, Alexandra Pecherkina1, Sofya Permyakova1, Erika Porubayeva1, Kristina Presnyakova1, Maksim Privalov1, Alesia Prutkogliadova1, Anna Pushkareva1, Arina Redya1, Anastasia Romanenko1, Filipp Roshchin1, Diana Salakhova1, Maria Sankova1, Ilona Sarukhanyan1, Viktoriia Savina1, Ekaterina Semeniako1, Valeriia Seregina1, Anna Shapovalova1, Khivit Sharbetova1, Nataliya Shishkina1, Anastasia Shvedova1, Valeriia Stener1, Valeria Ustyan1, Yana Valieva1, Maria Varaksina1, Katerina Varaksina1, Ekaterina Varlamova1, Natalia Vlasova1, Margarita Yegiyan1, Nadezhda Ziskina1, Daniella Zolochevskaya1, Elena Zuykova11. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia 2. ZA Bashlyaeva Children’s Municipal Clinical Hospital, Moscow, Russia The names of the authors are in alphabetic order.
Publisher Copyright:
© 2024, The Author(s).
PY - 2024/2/1
Y1 - 2024/2/1
N2 - BACKGROUND: Long-term health outcomes in children and young people (CYP) after COVID-19 infection are not well understood and studies with control groups exposed to other infections are lacking. This study aimed to investigate the incidence of post-COVID-19 condition (PCC) and incomplete recovery in CYP after hospital discharge and compare outcomes between different SARS-CoV-2 variants and non-SARS-CoV-2 infections.METHODS: A prospective exposure-stratified cohort study of individuals under 18 years old in Moscow, Russia. Exposed cohorts were paediatric patients admitted with laboratory-confirmed COVID-19 infection between April 2 and December 11, 2020 (Wuhan variant cohort) and between January 12 and February 19, 2022 (Omicron variant cohort). CYP admitted with respiratory and intestinal infections, but negative lateral flow rapid diagnostic test and PCR-test results for SARS-CoV-2, between January 12 and February 19, 2022, served as unexposed reference cohort. Comparison between the 'exposed cohorts' and 'reference cohort' was conducted using 1:1 matching by age and sex. Follow-up data were collected via telephone interviews with parents, utilising the long COVID paediatric protocol and survey developed by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). The WHO case definition was used to categorise PCC.RESULTS: Of 2595 CYP with confirmed COVID-19, 1707 (65.7%) participated in follow-up interviews, with 1183/1707 (69%) included in the final 'matched' analysis. The median follow-up time post-discharge was 6.7 months. The incidence of PCC was significantly higher in the Wuhan variant cohort (89.7 cases per 1000 person-months, 95% CI 64.3-120.3) compared to post-infection sequalae in the reference cohort (12.2 cases per 1000 person-months, 95% CI 4.9-21.9), whereas the difference with the Omicron variant cohort and reference cohort was not significant. The Wuhan cohort had higher incidence rates of dermatological, fatigue, gastrointestinal, sensory, and sleep manifestations, as well as behavioural and emotional problems than the reference cohort. The only significant difference between Omicron variant cohort and reference cohort was decreased school attendance. When comparing the Wuhan and Omicron variant cohorts, higher incidence of PCC and event rates of fatigue, decreased physical activity, and deterioration of relationships was observed. The rate of incomplete recovery was also significantly higher in the Wuhan variant cohort than in both the reference and the Omicron variant cohorts.CONCLUSIONS: Wuhan variant exhibited a propensity for inducing a broad spectrum of physical symptoms and emotional behavioural changes, suggesting a pronounced impact on long-term health outcomes. Conversely, the Omicron variant resulted in fewer post-infection effects no different from common seasonal viral illnesses. This may mean that the Omicron variant and subsequent variants might not lead to the same level of long-term health consequences as earlier variants.
AB - BACKGROUND: Long-term health outcomes in children and young people (CYP) after COVID-19 infection are not well understood and studies with control groups exposed to other infections are lacking. This study aimed to investigate the incidence of post-COVID-19 condition (PCC) and incomplete recovery in CYP after hospital discharge and compare outcomes between different SARS-CoV-2 variants and non-SARS-CoV-2 infections.METHODS: A prospective exposure-stratified cohort study of individuals under 18 years old in Moscow, Russia. Exposed cohorts were paediatric patients admitted with laboratory-confirmed COVID-19 infection between April 2 and December 11, 2020 (Wuhan variant cohort) and between January 12 and February 19, 2022 (Omicron variant cohort). CYP admitted with respiratory and intestinal infections, but negative lateral flow rapid diagnostic test and PCR-test results for SARS-CoV-2, between January 12 and February 19, 2022, served as unexposed reference cohort. Comparison between the 'exposed cohorts' and 'reference cohort' was conducted using 1:1 matching by age and sex. Follow-up data were collected via telephone interviews with parents, utilising the long COVID paediatric protocol and survey developed by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). The WHO case definition was used to categorise PCC.RESULTS: Of 2595 CYP with confirmed COVID-19, 1707 (65.7%) participated in follow-up interviews, with 1183/1707 (69%) included in the final 'matched' analysis. The median follow-up time post-discharge was 6.7 months. The incidence of PCC was significantly higher in the Wuhan variant cohort (89.7 cases per 1000 person-months, 95% CI 64.3-120.3) compared to post-infection sequalae in the reference cohort (12.2 cases per 1000 person-months, 95% CI 4.9-21.9), whereas the difference with the Omicron variant cohort and reference cohort was not significant. The Wuhan cohort had higher incidence rates of dermatological, fatigue, gastrointestinal, sensory, and sleep manifestations, as well as behavioural and emotional problems than the reference cohort. The only significant difference between Omicron variant cohort and reference cohort was decreased school attendance. When comparing the Wuhan and Omicron variant cohorts, higher incidence of PCC and event rates of fatigue, decreased physical activity, and deterioration of relationships was observed. The rate of incomplete recovery was also significantly higher in the Wuhan variant cohort than in both the reference and the Omicron variant cohorts.CONCLUSIONS: Wuhan variant exhibited a propensity for inducing a broad spectrum of physical symptoms and emotional behavioural changes, suggesting a pronounced impact on long-term health outcomes. Conversely, the Omicron variant resulted in fewer post-infection effects no different from common seasonal viral illnesses. This may mean that the Omicron variant and subsequent variants might not lead to the same level of long-term health consequences as earlier variants.
KW - Humans
KW - Child
KW - Adolescent
KW - Moscow/epidemiology
KW - Post-Acute COVID-19 Syndrome
KW - Incidence
KW - Prospective Studies
KW - SARS-CoV-2
KW - COVID-19/epidemiology
KW - Aftercare
KW - Cohort Studies
KW - Pandemics
KW - Patient Discharge
KW - Chronic Disease
KW - Fatigue
UR - http://www.scopus.com/inward/record.url?scp=85183730455&partnerID=8YFLogxK
U2 - 10.1186/s12916-023-03221-x
DO - 10.1186/s12916-023-03221-x
M3 - Article
C2 - 38302974
SN - 1741-7015
VL - 22
JO - BMC Medicine
JF - BMC Medicine
IS - 1
M1 - 48
ER -